Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Connection

Search Results to Frits Van Rhee

This is a "connection" page, showing the details of why an item matched the keywords from your search.

                     
                     

One or more keywords matched the following items that are connected to Van Rhee, Frits

Item TypeName
Academic Article DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma.
Academic Article Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis.
Academic Article Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning.
Academic Article Predicting long-term survival in multiple myeloma patients following autotransplants.
Academic Article Treatment advances in multiple myeloma.
Academic Article Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation.
Academic Article Con: allogeneic transplantation in multiple myeloma.
Academic Article Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma.
Academic Article Eight-year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1.
Academic Article Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities.
Academic Article TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3.
Academic Article Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications.
Academic Article Long-term outcome results of the first tandem autotransplant trial for multiple myeloma.
Academic Article A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma.
Academic Article Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies.
Academic Article Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3.
Academic Article Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation.
Academic Article CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma.
Academic Article Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma.
Academic Article Thalidomide in total therapy 2 overcomes inferior prognosis of myeloma with low expression of the glucocorticoid receptor gene NR3C1.
Academic Article Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease.
Academic Article Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation.
Academic Article Reiterative survival analyses of total therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment arms.
Academic Article Eruptive cherry hemangiomatosis associated with multicentric Castleman disease: a case report and diagnostic clue.
Academic Article A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease.
Academic Article Is double autologous stem-cell transplantation appropriate for new multiple myeloma patients?
Academic Article Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling.
Academic Article First thalidomide clinical trial in multiple myeloma: a decade.
Academic Article Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy.
Academic Article Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning.
Academic Article High-dose melphalan-based autotransplants for multiple myeloma: the Arkansas experience since 1989 in 3077 patients.
Academic Article Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2.
Academic Article Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103.
Concept Embolization, Therapeutic
Concept Treatment Outcome
Academic Article CNTO 328, a Novel- Anti-Interleukin-6 Monoclonal Antibody, is an Active Treatment for Castleman Disease
Academic Article Role of quantitative human cytomegalovirus PCR in predicting antiviral treatment response among high-risk hematopoietic stem-cell transplant recipients
Academic Article Patterns of central nervous system involvement in relapsed and refractory multiple myeloma.
Academic Article The future of autologous stem cell transplantation in myeloma.
Academic Article Siltuximab for multicentric Castleman disease.
Academic Article Curing myeloma at last: defining criteria and providing the evidence.
Academic Article Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial.
Academic Article Haematological cancer: Optimizing the treatment of multiple myeloma.
Academic Article Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease.
Academic Article A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease.
Academic Article Profile of elotuzumab and its potential in the treatment of multiple myeloma.
Academic Article The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.
Academic Article Extensive Remineralization of Large Pelvic Lytic Lesions Following Total Therapy Treatment in Patients With Multiple Myeloma.
Academic Article The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma.
Academic Article Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease.
Academic Article Immunologic approaches for the treatment of multiple myeloma.
Academic Article Treatment of Idiopathic Castleman Disease.
Academic Article Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma.
Academic Article International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.
Grant Potentiating Natural Killer Cell Anti-Myeloma Effects
Grant UARK 2002-36, An Open Label, Phase I Extension Study to Assess the Long-Term Safety and Tolerability of MRA as a Treatment for Castleman’s Disease
Grant 2004-04: Treatment with AMD3100 in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients to Increase the Number of Peripheral Blood Stem Cells When Giv
Grant Protocol CNTO328MCD2002; Phase 2, An Open-label, Multicenter Study to Evaluate the Safety of Long-term Treatment with Siltuximab in Subjects with Mult
Grant mTOR as a Central Regulator of iMCD Pathogenesis and Novel Therapeutic Target
Grant mTOR as a Central Regulator of iMCD Pathogenesis and Novel Therapeutic Target
Academic Article Long-term outcomes after autologous stem cell transplantation for multiple myeloma.
Grant A Phase II Trial for the Treatment of POEMS Syndrome with Daratumumab (207442)
Academic Article Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease.
Academic Article Monitoring treatment response and disease progression in myeloma with circulating cell-free DNA.
Academic Article Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab.
Academic Article International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease.
Academic Article ACCELERATE: A Patient-Powered Natural History Study Design Enabling Clinical and Therapeutic Discoveries in a Rare Disorder.
Academic Article PHF19 inhibition as a therapeutic target in multiple myeloma.
Academic Article Combinatorial treatment for unresectable unicentric Castleman disease.
Academic Article Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease.
Academic Article Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma.
Academic Article Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience.
Academic Article Gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective PROMMIS trial.

Search Criteria
  • Therapeutics